| Similar Articles |
|---|
 |
Chemistry World
September 25, 2013
Phillip Broadwith |
Nanobody inflammation drug attracts Abbvie Belgian biotech firm Ablynx has agreed a global licensing deal with Abbvie for its nanobody drug candidate ALX-0061.   |
Chemistry World
October 2, 2012
Andrew Turley |
Merck & Co $460m ion channel deal Merck & Co has struck a $460 million deal for rights to certain drug candidates developed by Belgian pharma company Ablynx. Merck will get rights to the monoclonal antibodies found to target a voltage gated ion channel. |
Chemistry World
August 5, 2015
Rebecca Trager |
Grabbing slices of the immuno-oncology pie An increasing number of companies are competing for a slice of the immuno-oncology market |
The Motley Fool
November 23, 2004
Brian Gorman |
AstraZeneca Buys Into Cambridge Antibody Cambridge Antibody scored a new alliance, although the deal threatens to make it a house divided. |
The Motley Fool
May 15, 2006
Brian Gorman |
AstraZeneca's Peer-Pressure Purchase The drug company seems to be paying a lot for Cambridge Antibody. Perhaps AstraZeneca didn't want to be left behind as its rivals bought up biotech technology -- but in its haste, it may be paying a steep price for what it's getting. Investors, take note. |
The Motley Fool
December 20, 2004
Brian Gorman |
Cambridge Antibody's Underdog Story Cambridge Antibody's legal success against Abbott Laboratories is a sign of the biotech industry's continued maturation. Cambridge Antibody's stock rocketed 14% on the news of its win. |
Chemistry World
March 15, 2011
Sarah Houlton |
Benlysta breaks 50 year Lupus drug drought The first new treatment for lupus erythematosus in half a century has been approved by the US Food and Drug Administration |
American Family Physician
December 1, 2003
Gill et al. |
Diagnosis of Systemic Lupus Erythematosus Systemic lupus erythematosus is a multisystem inflammatory disease that is often difficult to diagnose. Before the diagnosis can be established, four of 11 clinical and laboratory criteria must be met. |
American Family Physician
March 15, 2002
Stephen K. Lane & Joseph W. Gravel, Jr. |
Clinical Utility of Common Serum Rheumatologic Tests Many serum rheumatologic tests have been available for fewer than 10 years. As a result, some physicians are not fully aware of the indications, sensitivity, specificity, cost and clinical utility of these tests... |
